These genes included CCND3, DUSP10 and RAP1GAP, which may guide towards more rationalized choices with respect to immune-mediated therapy in HER2+ DCIS, such as targeted vaccine therapy. The gene discussed is RAP1GAP; the disease is ductal breast carcinoma in situ.